IN BRIEF: ImmuPharma shares fall as annual loss widens

ImmuPharma PLC - specialist drug discovery and development company - Widens its pretax loss to ...

Alliance News 25 May, 2022 | 3:53PM
Email Form Facebook Twitter LinkedIn RSS

ImmuPharma PLC - specialist drug discovery and development company - Widens its pretax loss to GBP8.9 million in 2021 from GBP7.2 million loss the previous year. Loss includes exceptional costs in respect of corporate reorganisation and respective settlement arrangements, company adds. Revenue drops 6.6% to GBP118,350 from GBP126,667. Research and development expenses surge to GBP3.7 million from GBP2.4 million. P140-related expenditure was the main reason for this increase. P140, also known as Llupuzor, is a potential treatment for Lupus. Company does not propose a dividend.

Chief Executive Tim McCarthy says: "With now a fully reviewed and assessed R&D development pipeline, we remain focused on bringing our two late-stage clinical assets, Lupuzor and P140 for CIDP closer to the market. Specifically, on Lupuzor, our partner Avion, is committed to moving this program into Phase 3 as soon as possible, following final discussions with the FDA and based on the positive readout of the recent PK study."

Current stock price: 5.30 pence, down 9.9% in London

12-month change: down 43%

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
ImmuPharma PLC 5.64 GBX 0.36 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.